Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tolly G Epstein

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Allergy and Asthma Proceedings|July 12, 2022
Safety of subcutaneous allergen immunotherapyDavid I Bernstein, Tolly G Epstein
Drugs|December 20, 2008
Current and emerging management options for hereditary angioedema in the USTolly G Epstein, Jonathan A Bernstein
Current Allergy and Asthma Reports|May 3, 2013
Immunotherapy safety: what have we learned from surveillance surveys?Jennifer A Kannan, Tolly G Epstein
The Journal of Allergy and Clinical Immunology. in Practice|October 31, 2025
Impact of Dose Adjustment After Gaps in Subcutaneous Immunotherapy: Update From the North American Immunotherapy Surveillance Study (2008-2023)Tolly G Epstein, Karen Berendts, David I Bernstein
The Journal of Allergy and Clinical Immunology. in Practice|November 6, 2016
Current Evidence on Safety and Practical Considerations for Administration of Sublingual Allergen Immunotherapy (SLIT) in the United StatesTolly G Epstein, Christopher Calabria, Linda S Cox, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 11, 2014
AAAAI/ACAAI surveillance study of subcutaneous immunotherapy, years 2008-2012: an update on fatal and nonfatal systemic allergic reactionsTolly G Epstein, Gary M Liss, Karen Murphy-Berendts, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|March 23, 2021
Risk factors for fatal and nonfatal reactions to immunotherapy (2008-2018): postinjection monitoring and severe asthmaTolly G Epstein, Karen Murphy-Berendts, Gary M Liss, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|March 8, 2016
Risk factors for fatal and nonfatal reactions to subcutaneous immunotherapy: National surveillance study on allergen immunotherapy (2008-2013)Tolly G Epstein, Gary M Liss, Karen Murphy-Berendts, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|October 25, 2011
Immediate and delayed-onset systemic reactions after subcutaneous immunotherapy injections: ACAAI/AAAAI surveillance study of subcutaneous immunotherapy: year 2Tolly G Epstein, Gary M Liss, Karen Murphy-Berendts, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 19, 2019
AAAAI/ACAAI Subcutaneous Immunotherapy Surveillance Study (2013-2017): Fatalities, Infections, Delayed Reactions, and Use of Epinephrine AutoinjectorsTolly G Epstein, Gary M Liss, Karen Murphy Berendts, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Allergy and Asthma Proceedings|July 12, 2022
Safety of subcutaneous allergen immunotherapyDavid I Bernstein, Tolly G Epstein
Drugs|December 20, 2008
Current and emerging management options for hereditary angioedema in the USTolly G Epstein, Jonathan A Bernstein
Current Allergy and Asthma Reports|May 3, 2013
Immunotherapy safety: what have we learned from surveillance surveys?Jennifer A Kannan, Tolly G Epstein
The Journal of Allergy and Clinical Immunology. in Practice|October 31, 2025
Impact of Dose Adjustment After Gaps in Subcutaneous Immunotherapy: Update From the North American Immunotherapy Surveillance Study (2008-2023)Tolly G Epstein, Karen Berendts, David I Bernstein
The Journal of Allergy and Clinical Immunology. in Practice|November 6, 2016
Current Evidence on Safety and Practical Considerations for Administration of Sublingual Allergen Immunotherapy (SLIT) in the United StatesTolly G Epstein, Christopher Calabria, Linda S Cox, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 11, 2014
AAAAI/ACAAI surveillance study of subcutaneous immunotherapy, years 2008-2012: an update on fatal and nonfatal systemic allergic reactionsTolly G Epstein, Gary M Liss, Karen Murphy-Berendts, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|March 23, 2021
Risk factors for fatal and nonfatal reactions to immunotherapy (2008-2018): postinjection monitoring and severe asthmaTolly G Epstein, Karen Murphy-Berendts, Gary M Liss, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|March 8, 2016
Risk factors for fatal and nonfatal reactions to subcutaneous immunotherapy: National surveillance study on allergen immunotherapy (2008-2013)Tolly G Epstein, Gary M Liss, Karen Murphy-Berendts, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|October 25, 2011
Immediate and delayed-onset systemic reactions after subcutaneous immunotherapy injections: ACAAI/AAAAI surveillance study of subcutaneous immunotherapy: year 2Tolly G Epstein, Gary M Liss, Karen Murphy-Berendts, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 19, 2019
AAAAI/ACAAI Subcutaneous Immunotherapy Surveillance Study (2013-2017): Fatalities, Infections, Delayed Reactions, and Use of Epinephrine AutoinjectorsTolly G Epstein, Gary M Liss, Karen Murphy Berendts, et al.
Pageof 2